Baxter International (NYSE:BAX) Issues FY 2025 Earnings Guidance

Baxter International (NYSE:BAX - Get Free Report) issued an update on its FY 2025 earnings guidance on Thursday morning. The company provided earnings per share (EPS) guidance of 2.450-2.550 for the period, compared to the consensus estimate of 2.460. The company issued revenue guidance of $11.2 billion-$11.3 billion, compared to the consensus revenue estimate of $11.2 billion. Baxter International also updated its Q1 2025 guidance to 0.470-0.500 EPS.

Baxter International Stock Up 1.3 %

NYSE:BAX traded up $0.43 on Friday, reaching $33.87. 7,264,381 shares of the stock traded hands, compared to its average volume of 4,927,193. The company has a market capitalization of $17.29 billion, a price-to-earnings ratio of 169.33, a PEG ratio of 9.83 and a beta of 0.61. The company has a current ratio of 1.43, a quick ratio of 1.09 and a debt-to-equity ratio of 1.31. Baxter International has a 12 month low of $28.33 and a 12 month high of $44.01. The company's fifty day simple moving average is $30.65 and its 200 day simple moving average is $34.14.

Baxter International (NYSE:BAX - Get Free Report) last released its quarterly earnings data on Thursday, February 20th. The medical instruments supplier reported $0.58 earnings per share for the quarter, beating analysts' consensus estimates of $0.52 by $0.06. The business had revenue of $2.75 billion during the quarter, compared to analyst estimates of $2.67 billion. Baxter International had a net margin of 0.77% and a return on equity of 18.30%. Equities analysts predict that Baxter International will post 1.83 EPS for the current fiscal year.

Baxter International Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, April 1st. Stockholders of record on Friday, February 28th will be issued a dividend of $0.17 per share. This represents a $0.68 dividend on an annualized basis and a dividend yield of 2.01%. The ex-dividend date is Friday, February 28th. Baxter International's payout ratio is presently 340.02%.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on BAX shares. Citigroup dropped their price target on shares of Baxter International from $37.00 to $35.00 and set a "neutral" rating on the stock in a report on Wednesday, December 11th. Stifel Nicolaus dropped their price target on shares of Baxter International from $46.00 to $38.00 and set a "buy" rating on the stock in a report on Monday, November 11th. Barclays started coverage on shares of Baxter International in a report on Thursday. They set an "overweight" rating and a $39.00 price target on the stock. StockNews.com downgraded shares of Baxter International from a "buy" rating to a "hold" rating in a report on Monday, November 11th. Finally, JPMorgan Chase & Co. dropped their price target on shares of Baxter International from $38.00 to $36.00 and set a "neutral" rating on the stock in a report on Friday. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and three have given a buy rating to the stock. According to MarketBeat, the company has an average rating of "Hold" and a consensus price target of $38.80.

Baxter International Company Profile

Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories.